Developing a new treatment for cognitive impairment related to Alzheimer's disease
GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: A Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular
This study is testing a new treatment called PNA5, which is designed to help people at risk for Alzheimer's and other types of dementia by improving brain blood flow and reducing inflammation, and your participation could help bring this promising therapy to those who need it.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Proneurogen, INC. NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10819329 on NIH RePORTER |
What this research studies
This research focuses on creating a new therapeutic called PNA5, which is designed to treat cognitive impairment in individuals at risk for Alzheimer's disease-related dementias and vascular contributions to cognitive impairment and dementia. The approach involves formulating an extended-release subcutaneous injection of PNA5 and conducting toxicology studies to ensure its safety. The therapy aims to improve brain blood flow and reduce inflammation by targeting specific receptors in the brain. Patients participating in this research may help advance a novel treatment that could address a significant unmet need in dementia care.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk for Alzheimer's disease-related dementias and have been diagnosed with cognitive impairment.
Not a fit: Patients who do not have cognitive impairment or are not at risk for Alzheimer's disease-related dementias may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from cognitive impairment related to Alzheimer's disease.
How similar studies have performed: Other research has shown promise in targeting neurovascular mechanisms to improve cognitive function, suggesting that this approach may be viable.
Where this research is happening
Tucson, United States
- Proneurogen, INC. — Tucson, United States (Active)
Researchers
- Principal investigator: Riley, Jeremy — Proneurogen, INC.
- Study coordinator: Riley, Jeremy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.